Table 4: Total cost for active surveillance and immediate treatment and possible cost savings corresponding to an annual cohort of 12 750 patients with prostate cancer stratified by patients’ treatment status

Treatment status	% (no.) of patients		Mean cost per patient, $		Total cost, $		Cost difference, $
Treatment status	% (no.) of patients		Active surveillance	Immediate treatment	Active surveillance	Immediate treatment	Per patient	Total
First year and 5-year follow-up
Patients requiring treatment	25.5	(3 247)	16 257	13 735	52 786 479	44 597 545	2 522	8 188 934*
Patients not requiring treatment	74.5	(9 503)	2 753	13 735	26 161 759	130 523 705	–10 982	–104 361 946†
Total	100.0	(12 750)	6 200	13 735	79 050 000	175 121 250	–7 535	–96 071 250‡
First year and 10-year follow-up
Patients requiring treatment	30.8	(3 922)	25 552	18 407	100 214 944	72 192 254	7 145	28 022 690*
Patients not requiring treatment	69.2	(8 828)	3 959	18 407	34 950 052	162 496 996	–14 448	–127 546 944†
Total	100.0	(12 750)	10 600	18 407	135 150 000	234 689 250	–7 807	–99 539 250‡

*Additional cost attributable to delayed treatment. †Cost savings attributable to active surveillance. ‡Total cost savings obtained through active surveillance.